Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Actavis plc - Product Pipeline Review - 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 106 | Code: MRS - 18605

Global Markets Directs, Actavis plc Product Pipeline Review 2014, provides an overview of the Actavis plcs pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Actavis plcs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


The report provides brief overview of Actavis plc including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Actavis plcs human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement
Latest news and deals relating to the Actavis plcs pipeline products

Reasons to buy

Evaluate Actavis plcs strategic position with total access to detailed information on its product pipeline
Assess the growth potential of Actavis plc in its therapy areas of focus
Identify new drug targets and therapeutic classes in the Actavis plcs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of Actavis plc and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of Actavis plc
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of Actavis plc and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues

Table Of Content 

Table of Contents 2
List of Tables 6
List of Figures 6
Actavis plc Snapshot 7
Actavis plc Overview 7
Key Information 7
Key Facts 7
Actavis plc- Research and Development Overview 8
Key Therapeutic Areas 8
Actavis plc- Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products- Monotherapy 12
Pipeline Products- Combination Treatment Modalities 13
Pipeline Products- Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Actavis plc- Pipeline Products Glance 17
Actavis plc- Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Filing rejected/Withdrawn Products/Combination Treatment Modalities 18
Phase III Products/Combination Treatment Modalities 19
Actavis plc- Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
Actavis plc- Early Stage Pipeline Products 22
IND/CTA Filed Products/Combination Treatment Modalities 22
Discovery Products/Combination Treatment Modalities 23
Actavis plc- Drug Profiles 24
(ceftazidime + avibactam) 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
(memantine hydrochloride ER + donepezil hydrochloride) 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
APT-1026 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
dalbavancin 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
(nebivolol + valsartan) 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
cariprazine 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
norethindrone 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
(aclidinium bromide + formoterol fumarate) 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
estradiol acetate 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
follitropin alfa 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
pancrelipase DR 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
udenafil 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ulipristal acetate 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
WC-2055 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(ceftaroline fosamil + avibactam) 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
(estrogen + progesterone) 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
albaconazole 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
cebranopadol 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
memantine hydrochloride 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
oxybutynin hydrochloride 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
sarecycline 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
EUR-1100 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Progesterone Vaginal Gel Second Generation 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
bezafibrate ER 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Actavis plc- Pipeline Analysis 62
Actavis plc- Pipeline Products by Target 62
Actavis plc- Pipeline Products by Route of Administration 64
Actavis plc- Pipeline Products by Molecule Type 65
Actavis plc- Pipeline Products by Mechanism of Action 66
Actavis plc- Recent Pipeline Updates 68
Actavis plc- Dormant Projects 90
Actavis plc - Discontinued Pipeline Products 92
Discontinued Pipeline Product Profiles 92
alvameline maleate 92
dexloxiglumide 92
ME-1036 92
neramexane mesylate 92
oglemilast 93
radiprodil 93
Actavis plc- Company Statement 94
Actavis plc- Locations And Subsidiaries 99
Head Office 99
Other Locations & Subsidiaries 99

Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables

Actavis plc, Key Information 7
Actavis plc, Key Facts 7
Actavis plc- Pipeline by Indication, 2014 9
Actavis plc- Pipeline by Stage of Development, 2014 11
Actavis plc- Monotherapy Products in Pipeline, 2014 12
Actavis plc- Combination Treatment Modalities in Pipeline, 2014 13
Actavis plc- Partnered Products in Pipeline, 2014 14
Actavis plc- Partnered Products/ Combination Treatment Modalities, 2014 15
Actavis plc- Pre-Registration, 2014 17
Actavis plc- Filing rejected/Withdrawn, 2014 18
Actavis plc- Phase III, 2014 19
Actavis plc- Phase II, 2014 20
Actavis plc- Phase I, 2014 21
Actavis plc- IND/CTA Filed, 2014 22
Actavis plc- Discovery, 2014 23
Actavis plc- Pipeline by Target, 2014 62
Actavis plc- Pipeline by Route of Administration, 2014 64
Actavis plc- Pipeline by Molecule Type, 2014 65
Actavis plc- Pipeline Products by Mechanism of Action, 2014 66
Actavis plc- Recent Pipeline Updates, 2014 68
Actavis plc- Dormant Developmental Projects,2014 90
Actavis plc - Discontinued Pipeline Products, 2014 92
Actavis plc, Subsidiaries 99

List of Figures

Actavis plc - Pipeline by Top 10 Indication, 2014 9
Actavis plc - Pipeline by Stage of Development, 2014 11
Actavis plc - Monotherapy Products in Pipeline, 2014 12
Actavis plc - Combination Treatment Modalities in Pipeline, 2014 13
Actavis plc - Partnered Products in Pipeline, 2014 14
Actavis plc - Pipeline by Top 10 Target, 2014 62
Actavis plc - Pipeline by Top 10 Route of Administration, 2014 64
Actavis plc - Pipeline by Top 10 Molecule Type, 2014 65
Actavis plc - Pipeline Products by Top 10 Mechanism of Action, 2014 66

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing